stockrow
Saturday 7 November 2026
Export SGMOQ’s income statement to Excel — free account
Sangamo Therapeutics, Inc.
SGMOQ Healthcare Biotechnology
Sangamo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.6 million, down 31.6% from fiscal 2024.
- Revenue
- −77.6%
- EPS
- +42.9%
- Free cash flow
- +26.2%
Quarter to March 2026, against a year earlier
0.11
0.00
0.00%
Follow SGMOQ
Alert me
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | 3 | 5 |
+8 more TTM periods Free account |
| 1,755.72% | (2,891.84%) | (474.34%) | (292.47%) | ||
| (168.79%) | (152.35%) | (107.67%) | (66.44%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
2,162.55% | (2,790.10%) | (1,230.67%) | (352.35%) | |
Average Days of Receivables |
9.22 | 3.42 | 5.81 | 1.66 | |
Free Cash Flow per Share |
(0.23) | (0.35) | (0.25) | (0.15) | |
Free Cash Flow |
(90.46) | (97.94) | (76.51) | (38.86) | |
Capital Expenditures |
(0.11) | (0.73) | (0.35) | (2.96) | |
| Other line items | |||||
Cash ROIC |
(1,048.04%) | (1,466.12%) | (208.07%) | (67.06%) | |
Accounts Receivable Turnover |
55.78 | 88.19 | 5.97 | 171.47 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.01) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
327.67% | 284.87% | 319.11% | 127.89% | |
Selling, General and Administrative Expense of Revenue |
91.57% | 88.20% | 112.53% | 49.02% | |
Share Based Compensation of Revenue |
21.63% | 22.95% | 31.12% | 13.98% | |
Operating CF/Net income |
0.73 | 0.79 | 0.71 | 0.57 | |
Depreciation/Fixed assets |
0.64 | 0.69 | 0.55 | 0.53 | |
Capex/Depreciation |
(0.02) | (0.10) | (0.04) | (0.35) | |
Revenue per Share |
0.09 | 0.14 | 0.11 | 0.32 | |
Operating CF per Share |
(0.23) | (0.35) | (0.25) | (0.14) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.02 | 0.01 | 0.04 |
Columns are period end dates